Needham & Company LLC Reiterates “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $6.00 target price on the stock. Needham & Company LLC’s target price indicates a potential upside of 270.37% from the stock’s previous close.

TSHA has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday. Finally, Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.62 on Thursday. The business has a 50-day simple moving average of $1.68 and a two-hundred day simple moving average of $1.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market cap of $332.01 million, a price-to-earnings ratio of 2.57 and a beta of 0.93. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. On average, analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently modified their holdings of the stock. Ground Swell Capital LLC purchased a new position in Taysha Gene Therapies during the fourth quarter valued at $25,000. Creative Planning purchased a new position in shares of Taysha Gene Therapies during the third quarter valued at about $28,000. Cibc World Markets Corp bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $28,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $31,000. Finally, Hsbc Holdings PLC lifted its position in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after buying an additional 8,076 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.